BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2085 related articles for article (PubMed ID: 33740362)

  • 21. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
    Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R
    Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
    Peterson L; Murugesan M; Nocon R; Hoang H; Bolton J; Laiteerapong N; Pollack H; Marsh J
    PLoS One; 2022; 17(10):e0276066. PubMed ID: 36256662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017.
    McClellan C; Moriya A; Simon K
    J Subst Abuse Treat; 2022 Jan; 132():108645. PubMed ID: 34728135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
    Klein MR; Darnall BD; You DS
    JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
    Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
    Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014.
    Burke LG; Zhou X; Boyle KL; Orav EJ; Bernson D; Hood ME; Land T; Bharel M; Frakt AB
    Addiction; 2020 Mar; 115(3):493-504. PubMed ID: 31691390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Larochelle MR
    J Subst Abuse Treat; 2022 Feb; 133():108540. PubMed ID: 34148756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States.
    Rasu RS; Vouthy K; Crowl AN; Stegeman AE; Fikru B; Bawa WA; Knell ME
    J Manag Care Spec Pharm; 2014 Sep; 20(9):921-8. PubMed ID: 25166291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study.
    As-Sanie S; Soliman AM; Evans K; Erpelding N; Lanier RK; Katz NP
    J Minim Invasive Gynecol; 2021 Feb; 28(2):297-306.e2. PubMed ID: 32531340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder.
    Foot C; Korthuis PT; Tsui JI; Luo SX; Chan B; Cook RR
    Addiction; 2024 Jan; 119(1):149-157. PubMed ID: 37712113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
    Cook RR; Torralva R; King C; Lum PJ; Tookes H; Foot C; Vergara-Rodriguez P; Rodriguez A; Fanucchi L; Lucas GM; Waddell EN; Korthuis PT
    Drug Alcohol Depend; 2021 Nov; 228():109077. PubMed ID: 34600253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 105.